MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17588359261426823

Медицинская библиотека · Therapeutic advances in medical oncology · 2026

Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience.

Salati Massimiliano, Borghi Eleonora, Cuoghi Costantini Riccardo, Parisi Alessandro, Lancianese Alessia, Palloni Andrea, Ricci Chiara, Garajova Ingrid, Orlandi Elena, Zurlo Ina Valeria, Petrillo Angelica, Diana Anna, Ricci Angela Dalia, Rizzo Alessandro, Manni Martina, Garrone Ornella, Dominici Massimo, Ghidini Michele

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Advanced biliary cancer (ABC) is still regarded as an incurable condition. However, the improved depth and duration of response enabled by chemo-immunotherapy may foster intensified strategies, including surgical procedures, radiotherapy and intra-arterial techniques.

OBJECTIVES

The prevalence, clinical features and treatment outcomes of ABC receiving multimodality treatment in the immunotherapy era are unknown.

DESIGN

Newly diagnosed ABC treated with chemo-immunotherapy and loco-regional procedures from February 2022 to December 2024 were retrospectively identified at 10 tertiary referral cancer centres in Italy.

METHODS

Categorical variables were compared using the chi-squared test, and the inverse probability of treatment weighting analysis was performed to reduce selection biases.

RESULTS

Of 241 ABC receiving first-line treatment, 12 (4.9%) fulfilled the inclusion criteria. The median age was 69 (range 36-80), and 9 patients (75%) had intrahepatic cholangiocarcinoma (iCCA). Ten (83.3%) presented with de novo unresectable ABC: 3 (25%) had locally advanced, and 7 (50.3%) had metastatic disease. The median number of metastatic sites was one, with lymph nodes being the most commonly involved location (41.6%, n = 5). Patients treated with intensified therapy were more likely to have low tumour burden (p = 0.03) and iCCA (p = 0.06). Overall, four patients underwent surgery, three transarterial radioembolization, three stereotactic body radiotherapy and two liver transplants. As of data cut-off, 11 patients were alive (91.6%), and five patients were disease-free (41.6%). After adjusting for age, gender, Eastern Cooperative Group Performance Status (ECOG PS), primary site, disease status and number of metastases, the overall survival for the multimodality strategy versus systemic treatment alone was not reached versus 14.1 months (p < 0.001).

CONCLUSION

This study, the first on multimodality treatment of ABC in the immunotherapy era, suggests that a highly selected subset of patients may achieve long-term disease control with an intensified approach. Oligometastatic patients and those affected by iCCA appear as the best candidates. Future studies are needed to confirm these preliminary findings.

Для цитирования: Salati Massimiliano, Borghi Eleonora, Cuoghi Costantini Riccardo, Parisi Alessandro, Lancianese Alessia, Palloni Andrea, Ricci Chiara, Garajova Ingrid, Orlandi Elena, Zurlo Ina Valeria, Petrillo Angelica, Diana Anna, Ricci Angela Dalia, Rizzo Alessandro, Manni Martina, Garrone Ornella, Dominici Massimo, Ghidini Michele. Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience.. Therapeutic advances in medical oncology. 2026. DOI: 10.1177/17588359261426823.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.